Data from multiple sources - Curated by Marshall Pearce - Last updated 06 June 2017

Latest news articles

Added 20 days ago Drug news

EU approves 10 mg once daily dose of Xarelto to prevent recurrent VTE.- Bayer + Janssen.

Bayer AG and its development partner Janssen Pharmaceuticals, Inc. announced that the European Commission (EC) has approved an update to...

Added 2 months ago Drug news

FDA issues refusal to file letter for Trevyent (treprostinil + PatchPump technology) for the treatment of pulmonary arterial hypertension.-SteadyMed Therapeutics.

SteadyMed Therapeutics announced receipt of a Refusal to File letter from the FDA relating to its New Drug Application (NDA)...

Added 4 months ago Drug news

FDA accepts priority review for Xarelto (rivaroxaban) in venous thromboembolism- Janssen

The FDA has accepted for Priority Review a supplemental New Drug Application (sNDA) for Xarelto (rivaroxaban), from Janssen, to include...

Search all news articles for Pulmonary heart disease
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Breakthrough Cancer Pain Learning Zone

Breakthrough Cancer Pain Learning Zone

Watch video hightlights from the BeCOn OWN 2017 event, including expert opinion, patient experience and panel discussions in the Breakthrough Cancer Pain Learning Zone.

Load more

Guidelines

Guideline on aspects of cancer-related venous thrombosis

The objective of this guideline is to provide healthcare professionals with clear guidance on the prevention and management of venous...

Added 2 years ago

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and can complicate the majority of cardiovascular...

Added 2 years ago

Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management

The aim of this guideline is to provide information, based on clinical evidence where available, regarding the immediate investigation and...

Added 2 years ago

Search all guidelines for Pulmonary heart disease
 

Journal articles

Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.

Background: Although many patients with venous thromboembolism require extended treatment, it is uncertain whether it is better to use full- or lower-intensity anticoagulation therapy or aspirin.

Added 1 month ago

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

Background: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention.

Added 1 month ago

Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.

Background: Adherence to oral anticoagulant (OAC) agents is important for patients with nonvalvular atrial fibrillation (NVAF) to prevent potentially severe adverse events.

Added 1 month ago

Search all journal articles for Pulmonary heart disease
 

Clinical trials

A Study to Investigate Different Doses of BAY1213790 to Prevent Blood Clots in Patients Undergoing Elective Total Knee Replacement Surgery (FOXTROT)

This study is to compare the study drug BAY1213790 to existing therapies, ie Enoxaparin or Apixaban for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).

Added 13 days ago

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) (EinsteinChoice)

This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy.
Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism)...

Added 4 years ago

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS)

The primary purpose of this study is to evaluate whether treatment with rivaroxaban and aspirin or rivaroxaban alone is better than aspirin alone in prevention of heart attacks, stroke or cardiovascular death...

Added 5 years ago

Search all clinical trials for Pulmonary heart disease
 
David Warriner

Dr David R Warriner is currently a Cardiology Registrar practising in South Yorkshire. Dr Warriner's clinical and research interests include heart failure, exercise physiology, physiological modelling, sports medicine and medical education. In his free time, Dr Warriner loves reading ... Read more

What is Overdiagnosis?

Overdiagnosis is the diagnosis of disease that will cause neither morbidity nor mortality during a patient’s lifetime. Doctors are trained to listen, examine, test, diagnose and treat patients, but we are not warned of the possible dangers of “diseases”, the diagnosis of which will not benefit the patient and may also lead to harm. I would argue that the Hippocratic oath, in particular “Primum non nocere” (first, do no harm) should be at the forefront of every clinician’s mind when seeing patients.